Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).

Arlene O. Siefker-Radtke,Andrea Necchi,Se Hoon Park,Jesús García-Donas,Robert Huddart,Earle Frederick Burgess,Mark D. Fleming,Arash Rezazadeh,Begoña Mellado,Sergei Varlamov,Monika Joshi,Ignacio Duran,Scott T. Tagawa,Yousef Zakharia,Keqin Qi,Manish Monga,Manu Sondhi,Anne OHagan,Yohann Loriot

Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).

2021

Arlene O. Siefker-Radtke
Andrea Necchi
Se Hoon Park
Jesús García-Donas
Robert Huddart
Earle Frederick Burgess
Mark D. Fleming
Arash Rezazadeh
Begoña Mellado
Sergei Varlamov
Monika Joshi
Ignacio Duran
Scott T. Tagawa
Yousef Zakharia
Keqin Qi
Manish Monga
Manu Sondhi
Anne OHagan
Yohann Loriot

426Background: Erdafitinib (ERDA), a pan-FGFR kinase inhibitor, was US FDA approved for adults with mUC with susceptible FGFR3/2 alterations (FGFRa) who progressed on ≥ 1 line of prior platinum-bas...

Keywords:

Metastatic Urothelial Carcinoma
Cancer research
locally advanced
Fibroblast growth factor receptor
Kinase
Adverse effect
Erdafitinib
in patient
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations